EUROPEAN BIOTECHNOLOGY | With the coronavirus pandemic mounting, experts are already warning of antimicrobial resistance as being the next, hidden crisis. The AMR community still urgently waits for substantial pull incentives. While the US DISARM act was pulled at the last minute from the country’s corona stimulus package, the UK’s NHS has started stakeholder engagement for its flat-rate model. Meanwhile, CARB-X-funded company Forge Therapeutics has closed a €170m deal with Roche and Paratek received a long-term BARDA contract. Typically, antibiotic work has not been seen as a high priority for big pharma in the past years, but with COVID-19, this may change.